OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Gastroenterology and Hepatology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Prevalence of Helicobacter pylori infection in China: A systematic review and meta‐analysis	127
Opening the black box of AI‐Medicine	99
Relationship between dietary patterns and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis	79
Post‐infection functional gastrointestinal disorders following coronavirus disease‐19: A case–control study	70
Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrhea‐predominant irritable bowel syndrome: A prospective, randomized trial	61
Impacts of the COVID‐19 pandemic on functional dyspepsia and irritable bowel syndrome: A population‐based survey	59
A review of non‐alcoholic fatty liver disease in non‐obese and lean individuals	57
Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta‐analysis	56
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease	53
Artificial intelligence in small bowel capsule endoscopy ‐ current status, challenges and future promise	51
Fecal microbiota transplantation therapy in Crohn's disease: Systematic review	50
Effect of remimazolam tosilate on early cognitive function in elderly patients undergoing upper gastrointestinal endoscopy	48
Artificial intelligence in prediction of non‐alcoholic fatty liver disease and fibrosis	47
Artificial intelligence in colonoscopy ‐ Now on the market. What's next?	46
Artificial intelligence in precision medicine in hepatology	45
Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease	40
Randomized clinical trial: 7‐day vonoprazan‐based versus 14‐day omeprazole‐based triple therapy for Helicobacter pylori	38
Diet and gut microbiome in gastrointestinal disease	38
Susceptibility‐guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta‐analysis	37
Gut microbiota‐derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19: An open‐label pilot study	37
Circulating tumor necrosis factor‐α levels in non‐alcoholic fatty liver disease: A systematic review and a meta‐analysis	36
Artificial intelligence assists identifying malignant versus benign liver lesions using contrast‐enhanced ultrasound	34
Contribution of upregulated aminoacyl‐tRNA biosynthesis to metabolic dysregulation in gastric cancer	31
Vonoprazan non‐inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients	30
A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis	30

Convolutional neural network‐based object detection model to identify gastrointestinal stromal tumors in endoscopic ultrasound images	30
Amoxicillin‐vonoprazan dual therapy forHelicobacter pylorieradication: A systematic review and meta‐analysis	30
The effect of increasing intestinal short‐chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: A systematic review	29
Gut microbiota composition associated with hepatic fibrosis in non‐obese patients with non‐alcoholic fatty liver disease	29
Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols dietversustraditional dietary advice for functional dyspepsia: a randomized controlled trial	29
Endoscopic ultrasound‐guided portal pressure gradient with liver biopsy: 6 years of endo‐hepatology in practice	29